Skip Navigation

JNCI Journal of the National Cancer Institute 2002 94(23):1807-1808; doi:10.1093/jnci/94.23.1807
© 2002 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Hishida, A.
Right arrow Articles by Tajima, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hishida, A.
Right arrow Articles by Tajima, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 94, No. 23, 1807-1808, December 4, 2002
© 2002 Oxford University Press

CORRESPONDENCE

Re: Population-Based, Case–Control Study of HER2 Genetic Polymorphism and Breast Cancer Risk

Asahi Hishida, Nobuyuki Hamajima, Hiroji Iwata, Keitaro Matsuo, Kaoru Hirose, Nobuhiko Emi, Kazuo Tajima

Affiliations of authors: A. Hishida, (Division of Epidemiology and Prevention, Aichi Cancer Center, Nagoya, Japan, and the Department of Molecular Medicine and Clinical Science, Nagoya University Graduate School of Medicine, Nagoya), N. Hamajima, K. Matsuo, K. Hirose, K. Tajima, Division of Epidemiology and Prevention, Aichi Cancer Center, Nagoya; N. Emi, Department of Molecular Medicine and Clinical Science, Nagoya University Graduate School of Medicine, Nagoya; H. Iwata, Department of Breast Surgery, Aichi Cancer Center, Nagoya.

Correspondence to: Asahi Hishida, M.D., Department of Molecular Medicine and Clinical Science, Nagoya University Graduate School of Medicine, Tsurumai-cho 65, Showa-ku, Nagoya 466–8550, Japan (e-mail: a-hishi@med.nagoya-u.ac.jp).

The first 10% of the full text of this article appears below.

HER2 is a well-known proto-oncogene encoding a transmembrane glycoprotein with tyrosine kinase activity. This protein is reported to have prognostic and predictive roles in breast cancer, and it is supposed to be involved with early pathogenesis of breast cancer. A polymorphism at codon 655 (Ile to Val; Ile655Val) in the transmembrane domain region of this gene was identified; a recent population-based . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
S Beauclair, P Formento, J. Fischel, W Lescaut, R Largillier, E Chamorey, P Hofman, J. Ferrero, G Pages, and G Milano
Role of the HER2 [Ile655Val] genetic polymorphism in tumorogenesis and in the risk of trastuzumab-related cardiotoxicity
Ann. Onc., August 1, 2007; 18(8): 1335 - 1341.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
W. Han, D. Kang, J. E. Lee, I. A. Park, J.-Y. Choi, K.-M. Lee, J. Y. Bae, S. Kim, E.-S. Shin, J. E. Lee, et al.
A Haplotype Analysis of HER-2 Gene Polymorphisms: Association with Breast Cancer Risk, HER-2 Protein Expression in the Tumor, and Disease Recurrence in Korea
Clin. Cancer Res., July 1, 2005; 11(13): 4775 - 4778.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
B. Frank, K. Hemminki, M. Wirtenberger, J. L. Bermejo, P. Bugert, R. Klaes, R. K. Schmutzler, B. Wappenschmidt, C. R. Bartram, and B. Burwinkel
The rare ERBB2 variant Ile654Val is associated with an increased familial breast cancer risk
Carcinogenesis, March 1, 2005; 26(3): 643 - 647.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
K. G. Montgomery, D. M. Gertig, S. W. Baxter, R. L. Milne, G. S. Dite, M. R. E. McCredie, G. G. Giles, M. C. Southey, J. L. Hopper, and I. G. Campbell
The HER2 I655V Polymorphism and Risk of Breast Cancer in Women < Age 40 Years
Cancer Epidemiol. Biomarkers Prev., October 1, 2003; 12(10): 1109 - 1111.
[Abstract] [Full Text] [PDF]